Earnings and Valuation of Autolus Therapeutics (NASDAQ:AUTL. Autolus Therapeutics plc Stock Forecast NASDAQ: AUTL Price Target and Analyst Ratings Most Recent Rating On Aug 02, 2021 "Mizuho" gave "$18.00" rating for AUTL. AUTL Stock Analysis - [Full Report] AUTL Chart by TradingView. Autolus Therapeutics says that this includes its "CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as next generation product therapies of. Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at . Get today's Autolus Therapeutics stock news. This price target is based on 6 analysts offering 12 month price targets for Autolus Therapeutics in the last 3 months. Earnings for Autolus Therapeutics are expected to decrease in the coming year, from ($2.69) to ($2.92) per share. Analysts covering Autolus Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -1.95 for the next financial year. AUTL 6.11 0.32 (4.98%) Post-Market 0.05 (0.82%) 2,821. Autolus Therapeutics plc Stock Add to Watchlist Overview Forecast Earnings Dividend Ownership $5.76 -0.45 (-7.25%) Updated Dec 3, 2021 1W - 7.99% 1M - 3.19% 3M - 20.77% 1Y - 45.45% AUTL Price $5.76 Fair Value Price N/A Market Cap $433.87M 52 Week Low $4.60 52 Week High $12.23 P/E -2.5x P/B 1.77x P/S 186.95x PEG N/A Dividend Yield N/A Revenue $2.55M Scan for strong stocks. AUTL Autolus Therapeutics Ltd - ADR — Stock Price and Discussion | Stocktwits. After the previous close at $5.56 (-1.59%), AUTL stock becomes bullish, reaching $7.08 with a +27.34% increase in the Pre-Market on Monday, Nov. 8, 2021.
The average price target is $15.40 with a high forecast of $21.00 and a low forecast of $12.00. Only 22.86% of the stock of Autolus Therapeutics is held by institutions. Free Signup: Advanced stock screener. So consider, for a moment, the misfortune of Autolus Therapeutics plc (NASDAQ:AUTL) investors who have held the stock for three years as it declined a whopping 84%. London, sept. 15, 2021 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), a clinical-stage biopharmaceutical company developing next-generation programmed t cell therapies, today announced that john h. johnson has been appointed as non-executive chairman of its board of directors, effective september 15, 2021. dr. martin murphy, who previously served as chairman, will continue to . Blackstone Life Sciences to invest $250 million in Autolus Therapeutics. Autolus Therapeutics plc (NASDAQ:AUTL) shares have surged 26.5% after a fund managed by Blackstone, Blackstone Life Sciences, agreed to invest up to $250 million in the company. CAR-T Cell Therapy Market Size 2021 Outlook - Post COVID 19 Scenarios | By -Aleta Biotherapeutics, Allogene Therapeutics, Anixa Biosciences Inc, Atara Biotherapeutics, Autolus Therapeutics Plc . Shares in Autolus Therapeutics are currently priced at $5.6. Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress - Conference call to be held on August 5, 2021 at 8:30 am ET/1:30 pm BST - August 05, 2021 07:00 ET . In June 2021, Autolus Therapeutics had US$216m in cash, and was debt-free. Sep 02, 2021. If so, you came to the right place. The company operates in two geographic regions, the United Kingdom and the United States. Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. Exploring Autolus Therapeutics plc (AUTL) stock? Syncona said Blackstone Life Science will invest $250 million in Autolus. Over the next 52 weeks, Autolus Therapeutics PLC has on average historically fallen by 41.6 % based on the past 3 years of stock performance. LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2021 financial results and operational highlights before open of U.S. markets on Wednesday, November 3, 2021. Or you can just type "AUTL news" to get the latest stock news. At that level they are trading at 0.168% discount to the analyst consensus target price of 0.00. London, sept. 15, 2021 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), a clinical-stage biopharmaceutical company developing next-generation programmed t cell therapies, today announced that john h. johnson has been appointed as non-executive chairman of its board of directors, effective september 15, 2021. dr. martin murphy, who previously served as chairman, will continue to . Blackstone triggers a 30% increase in Autolus Therapeutics shares. Stock Market Daily: Outlook Therapeutics stock has undergone multiple analysts rating changes in the recent past. Blackstone Life Sciences has also agreed to purchase $100 million of Autolus Therapeutics plc (NASDAQ:AUTL)'s stock. Autolus stock has underperformed since my last note and despite a catalyst-rich 2021, I think it may do well to reach $15 before YE. Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors. Volume has increased on the last day by 56 thousand shares but on falling prices. Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress Conference call to be held on November 3, 2021, at 8:30 am ET/12:30 pm GMT November 03, 2021 07:00 ET . Sep 15, 2021. William Blair analyst M. Phipps now forecasts that the company will post earnings per share of ($1.55) for the year, up from their prior […] Autolus Therapeutics plc is based in London,. News provided by. Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. William Blair analyst M. Phipps now expects that the company will earn ($1.60) per share for the year, up from their prior estimate of […] 1 week ago - GlobeNewsWire Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells 'Broker forecast' and 'Recent trades' provided by MoneyAM. So it had a cash runway of approximately 17 months from June 2021. Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. Key Data. Their forecasts range from $9.00 to $21.00. The company, currently valued at $482.97M, closed the last trade at $7.73 per share which meant it gained $0.88 on the day or 12.85% during that session. Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Key Data. About the company Rewards Trading at 91% below our estimate of its fair value Revenue is forecast to grow 74.57% per year Risk Analysis Currently unprofitable and not forecast to become profitable over the next 3 years
Autolus Therapeutics to participate in upcoming virtual investor conferences. The AUTL stock price is -122.38% off its Sep 02, 2021. Autolus Therapeutics PLC Stock Forecast. The post Blackstone triggers a 30% increase in Autolus Therapeutics shares appeared first on Invezz.
Shares of Autolus Therapeutics (NASDAQ: AUTL) surged 25% on Monday after the biopharmaceutical company struck a deal to receive financing of up to $250 million from Blackstone Life Sciences. If so, you came to the right place. Under. Sep 16, 2021. Morningstar Rating. Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, today announced that Blackstone Life Sciences ("Blackstone") has entered into a strategic collaboration and financing . Looking to buy or sell Autolus Therapeutics (AUTL)? Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors. So it had a cash runway of approximately 17 months from June 2021. . Long term, however, I'm maintaining my forecast for $30-50 . The current price level -47.42% lower than the highest price of $12.23 marked by the stock while trading over the past 52-weeks, whereas it is 39.78% higher than the lowest price of $4.60 the company dropped to over past 52-weeks. That average rating earns the stock an Analyst Ranking of 80, which means it ranks higher than 80 of stocks, based on data compiled by InvestorsObserver. Looking to buy or sell Autolus Therapeutics (AUTL)? Good News For Autolus Therapeutics plc (NASDAQ:AUTL): Stock Could Go Up 332.1% More stocksregister 5/19/2021. Rating as of Aug 27, 2021. William Blair analyst M. Phipps now expects that the company will earn ($1.60) per share for the year, up from their prior estimate of […] Autolus Therapeutics PLC Sponsored ADR (AUTL) was a big mover last session on higher-than-average trading volume. 6 equities research analysts have issued twelve-month price targets for Autolus Therapeutics' shares. Autolus Therapeutics plc - AUTL stock news. In the last year, its cash burn was US$154m. Zacks -5.15%. Investing.com — U.K.-based biopharmaceutical firm Autolus Therapeutics Ltd (NASDAQ:AUTL) announced Monday that Blackstone (NYSE:BX) will invest as much as $250 million in the company to support .
AUTL Stock Predictions, Articles, and Autolus Therapeutics Plc ADR News From the Web Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge Sep 16, 2021. Shares of Autolus Therapeutics plc (NASDAQ: AUTL) jumped about 30% in premarket trading on Monday after it said Blackstone Life Sciences agreed to invest up to $250 million to fund the development of its new therapy for Leukemia. The price has fallen in 6 of the last 10 days, but is still up by 13.28% over the past 2 weeks. In the past three months, Autolus Therapeutics insiders have not sold or bought any company stock. Autolus Therapeutics PLC (AUTL:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. $150 million out of the total . View AUTL's stock price, price target, dividend, earnings, financials, forecast, insider trades, and SEC filings at StockEarnings.
LONDON and CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell . View Autolus Therapeutics AUTL investment & stock information. News. Autolus Therapeutics plc (NASDAQ:AUTL) - Stock analysts at William Blair upped their FY2021 EPS estimates for shares of Autolus Therapeutics in a research note issued to investors on Monday, November 8th. In order for the stock price to hit the forecast high, the stock would need to plunge -361.29% from its current level, while the stock would need to crash -15.32% from its current level to reach the projected low. Last 30 Days Show entries Showing 1 to 10 of 28 entries Previous 1 2 3 Next AUTL Stock Trend This chart shows the closing price for AUTL for . Nov-30-20 07:00AM. This suggests a possible upside of 154.6% from the stock's current price. Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK.
News. Autolus Therapeutics to participate in upcoming virtual investor conferences. The latest Autolus Therapeutics Ltd ADS Each Rep 1 Ord Shs share price. In the chart below, we can see that institutional . Thinking about buying stock in Pioneer Power Solutions, Lucid Group, TAL Education, Meten Holding, or Autolus Therapeutics? AUTL has generated -$2.29 earnings per share over the last four quarters. In June 2021, Autolus Therapeutics had US$216m in cash, and was debt-free. 08 November 2021. News. Autolus Therapeutics PLC has fallen lower in 3 of those 3 years over the subsequent 52 week period, corresponding to a historical accuracy of 100 % The news comes shortly after Autolus Therapeutics said it will set up a dedicated manufacturing facility in Stevenage in a bid to establish "global commercial launch capacity" for obe-cel. Description: Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer.The company's clinical-stage pipeline comprises five programs: AUTO1, AUTO1/22, AUTO3, AUTO4 and AUTO6. Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine. Autolus Therapeutics Ltd - ADR NASDAQ Updated Dec 1, 2021 11:32 PM. Interested in getting the full scoop on AUTL, including earnings and dividends, stock forecast, buy or sell analysis and key stats?
Hells Angels News Canada 2021,
8 Oz Paper Soup Cups With Lids,
Are Jesse And Yumyulack Related,
Idp Project For Mechanical Engineering,
Is Harris Yulin Still Alive,
Rhys Williams Wales Football,